Logotype for iSpecimen Inc

iSpecimen (ISPC) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for iSpecimen Inc

Q3 2026 earnings summary

17 Nov, 2026

Executive summary

  • Q3 revenue rose 129% YoY to $244,034, while nine-month revenue fell 71% to $551,983 as specimen volume declined; nine-month net loss widened 7% to $5.85M.

  • Available cash was $5.56M at September 30, 2026, and management reported substantial doubt about continuing as a going concern for one year after issuance.

Financial highlights

  • Q3 operating loss was $2.20M vs. $2.83M YoY; net loss was $2.21M vs. $2.78M, and basic and diluted EPS was $(1.03) vs. $(19.05), split-adjusted.

  • Nine-month operating loss was $6.10M vs. $6.29M YoY; net loss was $5.85M vs. $5.49M, and basic and diluted EPS was $(4.49) vs. $(61.54), split-adjusted.

  • Q3 revenue increased 129% to $244,034; nine-month revenue declined 71% to $551,983, with specimen volume down 61% to 1,977 and average selling price down 24% to ~$279.

  • Nine-month operating expenses fell 19% to $6.65M; sales and marketing increased 99% to $3.47M, while technology fell 48% to $841,426.

  • Cash was $5.56M, working capital $870,936, total assets $9.70M, and stockholders’ equity $4.07M at September 30, 2026.

Outlook and guidance

  • Plans include driving revenue through revenue-enhancement initiatives, reducing and managing expenses, deferring projects and capital expenditures, and eliminating future operating costs; success is not assured.

  • Commercial priorities include account-based selling, an outbound sales team, closer sales-marketing coordination, and faster quote conversion; next-day quotes had a 44% quote-to-order conversion ratio through Q3 2026.

  • Management intends to use existing cash for supply-network growth, increased sales and marketing presence, operational scaling, working capital, and general corporate purposes.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from iSpecimen